Manteia researches deep learning, data technologies, and traditional algorithms to build tools for radiotherapy. Its core products include an adaptive radiation therapy (ART) system and related product modules, a library of common radiotherapy algorithm components and plugins, and deep-learning-based real-time analysis and training systems. These products are designed to improve radiotherapy precision and clinical efficiency. Manteia recently completed a B round raising ¥110 million. The financing was led by Zhongke Haichuang, associated with the Ministry of Science and Technology's Achievement Transformation Guidance Fund, with participation from Yangming Capital and industry cooperation institutions. The article does not disclose prior rounds, valuation, operating metrics, or the specific instruments used in the deal. Manteia develops adaptive radiotherapy (ART) systems, common product modules, algorithm component libraries, and plug-ins that simulate clinical logic to solve clinical problems. Its product suite includes intelligent planning tools such as automatic contouring, automatic planning, and biological optimization. The team's adaptive radiotherapy research group was established in 2011; the company operates independent and joint laboratories, about 30 global joint R&D units, over 80 research projects, and more than 20 international joint projects. Within one year Manteia obtained product registration in four mainstream markets—FDA, NMPA, CE, and KFDA—and has achieved ISO13485 and MDSAP quality-system certifications. The company has entered more than 300 leading hospitals worldwide, including in the United States, Canada, and South Korea, serving thousands of patients every day. Manteia completed a financing round of RMB 100 million jointly invested by Danlu Capital and Deyi Capital.

Total raised

$31M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2024